evidence: Citation: Stowe J, Miller E, Andrews N, Whitaker HJ (2023) Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England. PLoS Med 20(6): e1004245. https://doi.org/10.1371/journal.pmed.1004245 [...] The attributable risk estimates from the SCCS analysis for hospital admissions for myocarditis or pericarditis after vaccination and after a SARS-CoV-2 infection are shown in Table 4 for exposures with p < 0.001 for an elevated RI estimate. Attributable risk estimates for admission for myocarditis or pericarditis within 0 to 27 days of a laboratory-confirmed were 10.2 and 18.1 per million in 16 to 39 and ≥40 year olds, respectively. [...] - 6. Karlstad Ø, Hovi P, Husby A, Härkänen T, Marie Selmer R, Pihlström N, et al. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents. JAMA Cardiol. 2022;7(6):600–612. pmid:35442390 - 7. Wong HL, Hu M, Zhou CK, Lloyd PC, Amend KL, Beachler DC, et al. Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases. Lancet. 2022 Jun 11;399(10342):2191–2199. pmid:35691322; PMCID: PMC9183215.